CD4 and neoplasm: Downregulation of c-FLIPL and PD-1 therapy alone could increase the CD8+/CD4+ ratio to a similar degree, however, the percentage of CD8+ T cells appear to be increased to a greater extent in B16- c-FLIPL-shRNA tumor groups (Figure 4B).